Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-10-10
2006-10-10
Navarro, Mark (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S300000, C530S350000, C530S388100, C435S007100, C424S130100
Reexamination Certificate
active
07119172
ABSTRACT:
The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically toP. aeruginosamucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy ofP. aeruginosainfection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains ofP. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
REFERENCES:
patent: 4578458 (1986-03-01), Pier
patent: 4902616 (1990-02-01), Fournier et al.
patent: 5055455 (1991-10-01), Pier
patent: 5233024 (1993-08-01), Schreiber et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5407796 (1995-04-01), Cutting et al.
patent: 5434086 (1995-07-01), Collins et al.
patent: 5502039 (1996-03-01), Pier
patent: 5589591 (1996-12-01), Lewis
patent: 5980910 (1999-11-01), Pier
patent: 5989542 (1999-11-01), Pier et al.
patent: 6245735 (2001-06-01), Pier
patent: 6399066 (2002-06-01), Pier
patent: 6743431 (2004-06-01), Pier
patent: 6825178 (2004-11-01), Pier
patent: 2002/0009457 (2002-01-01), Bowersock et al.
patent: 2002/0119166 (2002-08-01), Pier et al.
patent: 2003/0124631 (2003-07-01), Pier et al.
patent: 2004/0091494 (2004-05-01), Pier et al.
patent: 0 120 532 (1984-10-01), None
patent: WO91/02796 (1991-03-01), None
patent: WO92/18162 (1992-10-01), None
patent: WO93/12240 (1993-06-01), None
patent: WO93/17040 (1993-09-01), None
patent: WO93/24641 (1993-12-01), None
patent: WO94/04669 (1994-03-01), None
patent: WO94/04671 (1994-03-01), None
patent: WO 94/08617 (1994-04-01), None
patent: WO94/25607 (1994-11-01), None
patent: WO95/06743 (1995-03-01), None
patent: WO95/13365 (1995-05-01), None
patent: WO95/25796 (1995-09-01), None
patent: WO95/28494 (1995-10-01), None
patent: WO 02/094854 (2002-11-01), None
Albus et al., Increased levels of IgG subclasses specific forPseudomonas aeruginosaexoenzyme and polysaccharide antigens in chronically infected patients with cystic fibrosis. APMIS. Dec. 1989;97(12):1146-8.
Des Jardins et al., Abstracts from the annual meeting. Am Soc Microbiol. 1989; p. 49 (abstract B-110).
Diamond et al., A cross-species analysis of the cystic fibrosis transmembrane conductance regulator. Potential functional domains and regulatory sites. J Biol Chem. Nov. 25, 1991;266(33):22761-9.
Garner et al., Immunogenic properties ofPseudomonas aeruginosamucoid exopolysaccharide. Infect Immun. Jun. 1990;58(6):1835-42.
Irvin et al., Immunochemical examination of thePseudomonas aeruginosaglycocalyx: a monoclonal antibody which recognizes L-guluronic acid residues of alginic acid. Can J Microbiol. Mar. 1985;31(3):268-75.
Johansen et al., Experimental immunization withPseudomonas aeruginosaalginate induces IgA and IgG antibody responses. APMIS. Dec. 1991;99(12):1061-8.
Mai et al., Inhibition of adherence of mucoidPseudomonas aeruginosaby alginase, specific monoclonal antibodies, and antibiotics. Infect Immun. Oct. 1993;61(10):4338-43.
Mai et al., Suppression of lymphocyte and neutrophil functions byPseudomonas aeruginosamucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments. Infect Immun. Feb. 1993;61(2):559-64.
Meluleni et al., Comparative susceptibility ofPseudomonas aerouginosa. 94th Meeting of the American Society for Microbiology. 1994;94:160. Abstract E-94.
Pier et al., Rationale for development of immunotherapies that target mucoidPseudomonas aeruginosainfection in cystic fibrosis patients. Behring Inst Mitt. Feb. 1997;(98):350-60.
Pier et al., Human monoclonal antibodies toPseudomonas aeruginosaalginate that protect against infection by both mucoid and nonmucoid strains. J Immunol. Nov. 1, 2004;173(9):5671-8.
Pier et al., Vaccine potential ofPseudomonas aeruginosamucoid exopolysaccharide (alginate). Antibiot Chemother. 1991;44:136-42.
Pier et al., Isolation and characterization of a high-molecular-weight polysaccharide from the slime ofPseudomonas aeruginosa. Infect. Immun. Dec. 1978;22(3):908-18.
Pier et al., Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide fromPseudomonas aeruginosa. Infect Immun. Dec. 1978;22(3):919-25.
Pier et al., Further purification and characterization of high-molecular-weight polysaccharide fromPseudomonas aeruginosa. Infect Immun. Dec. 1983;42(3):936-41.
Pier et al., Analysis of naturally occurring antibodies to mucoidPseudomonas aeruginosain cystic fibrosis patients. J Infect Dis. Feb. 1996;173(2):513-5.
Pier et al., Immune complexes from immunized mice and infected cystic and fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody toPseudomonas aeruginosa. J Clin Invest. Mar. 1993;91(3):1079-87.
Pressler et al., Immunoglobulin allotypes and IgG antibody response toPseudomonas aeruginosaantigens in chronically infected cystic fibrosis patients. Clin Exp Immunol. Nov. 1992;90(2):209-14.
Saunders et al., Development of monoclonal antibodies to the mucoid exopolysaccharide ofPseudomonas aeruginosa. Abstr Annu Meet Am Soc Microbiol. 1986;86:45. Abstract B-129.
Theilacker et al., Construction and characterization of aPseudomonas aeruginosamucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun. Jul. 2003;71(7):3875-84.
Tosi et al., Cross-sectional and longitudinal studies of naturally occurring antibodies toPseudomonas aeruginosain cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis. Aug. 1995;172(2):453-61.
Pier et al., “Complement deposition by antibodies toPseudomonas aeruginosamucoid exopolysaccharide (MEP) and by non-MEP specific opsonins”,J. Immunology, 147: 1869-1876, 1991.
Schreiber et al., “Induction of opsonic antibodies toPseudomonas aeruginosamucoid exopolysaccharide by an anti-idiotype monoclonal antibody”,Journal of Infectious Diseases, 164: 507-514, 1991.
Parad et al., Pulmonary outcome of cystic fibrosis is influenced primarily by mucoidPseudomonas aeruginosainfection and immune status and only modestly by genotype,Infection and Immunity, 67: 4744-4750; 1999.
Meluleni, et al., “MucoidPseudomonas aeruginosagrowing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients”,J. Immunology, 155(4): 2029-38; 1995.
Preston et al., “Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific forPseudomonas aeruginosaserogroup O6 lipopolysaccharide”,Infection and Immunity, 66(9): 4137-4142, 1998.
Preston et al., “Prophylactic and therapeutic efficacy of immunoglobulin G antibodies toPseudomonas aeruginosalipopolysaccharide against murine experimental corneal infection”,Investigative Ophthalmology and Visual Science, 38(7): 1418-1425, 1997. Abstract Only.
Pollack et al., “Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies toPseudomonas aeruginosalipopolysaccharide”,Infection and Immunity, 63(11): 4481-4488, 1995.
Boucher, R et al., “Gene Therapy for Cystic Fibrosis Using E1-Deleted Adenovirus: A Phase 1 Trial in the Nasal Cavity”,Human Gene Therapy, 1994, 5:615-639.
Boyer, D et al., Poster Presentation. American Thoracic Society, #D33, May 17, 2002.
Cheng, KH et al., “Immunoglobulin A antibodies againstPseudomonas aeruginosain the tear fluid of contact lens wearers”,Invest Ophthalmol Vis SciSep. 1996:37 (10): 2081-8.
Ciofu, O et al., “Avidity of anti-P aeruginosaantibodies during chronic infection in patients with cystic fibrosis”,Thorax1999; 54: 141-144.
Davies, J et al., “Reduction in the adherence ofPseudomonas aeruginosato native cystic fibrosis epithelium with anti-asialoGM
Cavacini Lisa
Pier Gerald B.
Posner Marshall
Preston Michael J.
Beth Israel Deaconess Medical Center Inc.
Navarro Mark
The Brigham and Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
LandOfFree
P. aeruginosa mucoid exopolysaccharide specific binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P. aeruginosa mucoid exopolysaccharide specific binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P. aeruginosa mucoid exopolysaccharide specific binding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3691173